Antoniadi, Anna Markella
Galvin, Miriam
Heverin, Mark
Hardiman, Orla
Mooney, Catherine
Funding for this research was provided by:
Science Foundation Ireland (16/RC/3948)
Irish Health Research Board (ICE/2012/6)
American ALS Association (17 CM-324)
Article History
Received: 13 February 2021
Accepted: 27 May 2021
First Online: 10 June 2021
Competing interests
: O.H. is a lead investigator on projects that have received research funding from the following pharmaceutical companies and CROs: Biogen, Ionis, Cytokinetics, Novartis, Takeda, Merk, IQVIA, ICON. O.H. has consulted and received honoraria from the following companies: Biogen, Cytokinetics, Denali, Orphazyme, Neurosense, Aclipse, Wave Pharmaceuticals, Novartis. O.H. is the Editor in Chief of the Journal Amyotrophic Lateral Sclerosis and the Frontotemporal Degenerations. A.A., M.G., M.H. and C.M. declare no competing interests.